03:21 AM EST, 01/13/2025 (MT Newswires) -- GSK (GSK) has agreed to acquire oncology company IDRx for up to $1.15 billion, the companies said Monday.

The consideration includes $1 billion in an upfront payment, and up to $150 million in potential regulatory-based milestone payments. GSK will also be responsible for milestone and royalty payments owed to Merck KGaA related to IDRX-42, a treatment candidate for gastrointestinal stromal tumors.

The deal is subject to regulatory clearances, and other customary conditions.